10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $40.6B | $49.2B | $57.2B | $64.2B | $71.9B |
| EBIT | $16.5B | $19.9B | $23.2B | $26.0B | $29.1B |
| Tax | $2.3B | $2.8B | $3.3B | $3.7B | $4.1B |
| NOPAT | $14.1B | $17.1B | $19.9B | $22.4B | $25.0B |
| + Depreciation | $4.8B | $5.8B | $6.7B | $7.6B | $8.5B |
| - Capex | $1.3B | $1.6B | $1.8B | $2.1B | $2.3B |
| - Δ NWC | $947M | $1.1B | $939M | $821M | $512M |
| Free Cash Flow | $16.7B | $20.3B | $23.9B | $27.0B | $30.7B |
| Discount Factor | 0.944 | 0.840 | 0.748 | 0.666 | 0.560 |
| Present Value | $15.7B | $17.0B | $17.9B | $18.0B | $17.2B |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 3.97% | $2,202.68 | $2,119.84 | $2,040.86 | $1,965.55 | $1,893.71 |
| 4.97% | $1,444.46 | $1,696.03 | $2,040.86 | $1,965.55 | $1,893.71 |
| 5.97% | $1,058.70 | $1,181.67 | $1,346.06 | $1,577.05 | $1,893.71 |
| 6.97% | $834.66 | $904.71 | $992.42 | $1,105.42 | $1,256.49 |
| 7.97% | $690.47 | $734.30 | $786.95 | $851.37 | $932.04 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth10.55%
Year 3 Revenue Growth9.67%
Year 5 Revenue Growth7.19%
Year 7 Revenue Growth5.52%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
EBIT Margin40.52%
Tax Rate14.09%
Capex / Revenue3.20%
NWC / Revenue24.44%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 18x EV/EBITDA (S&P 500: 22x P/E)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.